PCVX Q1 2021 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$21M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$382M

Total Liabilities

$55M

Stockholders' Equity

$327M

Cash & Equivalents

$199M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$28M	+16.1%
Net Income	-$21M	-$27M	+21.8%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%